Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
PERSEVERE- a Trial to Evaluate AMDS in Acute DeBakey Type I Dissection
NCT05174767 · View on ClinicalTrials.gov ↗
Study Summary
Prospective, non-randomized, multicenter clinical investigation to assess the safety and effectiveness of AMDS in the treatment of patients with acute DeBakey type I dissection, with evidence of malperfusion, through open surgical repair.
Conditions Studied
Interventions
- DEVICE AMDS
Study Locations (20)
New York
- Mount Sinai Hospital — New York
- Columbia University Irving Medical Center/New York Presbyterian Hospital — New York
- Northwell — New York
- Montefiore Einstein Medical — The Bronx
California
- University of Southern California — Los Angeles
- Stanford University — Palo Alto
Pennsylvania
- University of Pennsylvania — Philadelphia
- University of Pittsburgh Medical Center — Pittsburgh
Alabama
- University of Alabama at Birmingham — Birmingham
Colorado
- University of Colorado — Aurora
Connecticut
- Hartford Hospital — Hartford
Florida
- University of Florida — Gainesville
Georgia
- Emory University Medical Center — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2029-12-06 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05174767
The ClinicalTrials.gov registry entry for NCT05174767 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Artivion, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Acute Aortic Dissection appearing as the primary indexed condition, and to 1 intervention — of which AMDS is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05174767 reports 20 study locations spanning 15 distinct geographic areas — top geographies include New York, California, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05174767 about?
NCT05174767 is a clinical study titled "PERSEVERE- a Trial to Evaluate AMDS in Acute DeBakey Type I Dissection". Prospective, non-randomized, multicenter clinical investigation to assess the safety and effectiveness of AMDS in the treatment of patients with acute DeBakey type I dissection, with evidence of malperfusion, through open surgical repair.
What is the current status of trial NCT05174767?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 115 participants. The study started on 2022-05-27. Estimated completion is 2029-12-06.
What conditions does trial NCT05174767 study?
This clinical trial studies the following conditions: Acute Aortic Dissection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05174767?
The interventions under investigation include: AMDS (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05174767?
This trial is sponsored by Artivion, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05174767 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.